HCW Biologics (HCWB) Change in Accured Expenses (2020 - 2025)

HCW Biologics (HCWB) has 6 years of Change in Accured Expenses data on file, last reported at -$339231.0 in Q4 2025.

• Quarterly Change in Accured Expenses rose 33.28% year-over-year to -$339231.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.5 million (down 129.25% YoY) and the FY2025 annual result came in at -$3.5 million, down 129.25% from the prior year.
• Change in Accured Expenses climbed to -$339231.0 in Q4 2025, from -$362123.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $9.4 million in Q2 2024 to a low of -$2.4 million in Q1 2025.
• A 5-year average of $616322.1 and a median of $488163.0 in 2021 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses plunged 250.21% — and 2024, when it soared 1801.51%.
• Tracing HCWB's Change in Accured Expenses over 5 years: stood at -$72913.0 in 2021, then surged by 951.96% to $621187.0 in 2022, then soared by 97.45% to $1.2 million in 2023, then plunged by 141.45% to -$508404.0 in 2024, then jumped by 33.28% to -$339231.0 in 2025.
• The last three Change in Accured Expenses figures came in at -$339231.0 (Q4 2025), -$362123.0 (Q3 2025), and -$373905.0 (Q2 2025), per Business Quant data.